Moss, 10 July 2025
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the second quarter and first half year of 2025.
Highlights include:
Sales of NOK 43.6 million in 2Q25, up 14% vs 2Q24 (14% organic growth). Revenue of NOK 88.1 million in 1H25 up 15% vs 1H24 (13% organic growth).
Sales of Cystatin C increased with 31% in 2Q25 compared to 2Q24. Strong increase in sales to China indicates a return towards a normalised supply situation.
Continued US sales growth of 156% in 2Q25, and 94% in 1H25 with additional new accounts established for Cystatin C and cCRP across several market segments.
EBITDA of NOK 1.7 million in 2Q25 versus NOK 6.8 million in 2Q24. EBITDA of NOK 15.7 million in 1H25 versus NOK 11.6 million in 1H24.
Production issues related to raw materials resulted in a gross margin of 44%, down from 57% in 2Q24. Gross margin for 1H25 of 54%, versus 55% in 1H24.
Webcast
The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company's website:
https://www.gentian.com/investor-relation/presentations
The webcast will also be available on the company website after the presentation.
2Q2025 Report
2Q 2025 Presentation
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
About Gentian Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunoassays, specifically for infections, inflammation, kidney failure and congestive heart failure. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.